Caris Life Sciences Announces Dual Listing on NYSE Texas
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. Shares will keep trading on NASDAQ and also list on NYSE Texas under the CAI ticker, aiming for greater investor exposure, especially in Texas.
Positive
- Dual listing on NYSE Texas effective June 17, 2026
- Maintains NASDAQ primary listing while expanding investor access under ticker CAI
Negative
- None.
News Market Reaction – CAI
In the Jun 16 session, CAI declined 1.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Share repurchase plan | Positive | +1.6% | Board authorized up to $100M in common stock repurchases. |
| May 26 | Branding/patient campaign | Positive | -0.2% | Launch of "Behind the Diagnosis" campaign highlighting GPSai impact. |
| May 15 | Clinical value study | Positive | -4.6% | Study on Caris Lookback Program showing new therapy eligibility findings. |
| May 11 | WES TMB outcomes study | Positive | -1.3% | Data showing WES-based TMB better predicts pembrolizumab benefit. |
| May 08 | Regulatory application | Positive | -1.3% | Application for Caris Assure blood-based profiling authorization in New York. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive or strategic news (studies, applications, buybacks) often saw muted or negative next-day moves, with only the buyback announcement aligning positively.
Over the past months, Caris reported several precision medicine milestones, including clinical studies on MI Cancer Seek and Whole Exome Sequencing, and an application for Caris Assure testing in New York. On June 8, 2026, the board authorized a $100M share repurchase program, which saw a modest positive reaction. Earlier scientific updates in May tended to be followed by small negative price moves, indicating that fundamental advances have not consistently translated into immediate market strength.
Key Terms
whole genome sequencing medical
artificial intelligence technical
machine learning technical
molecular profiling medical
precision medicine medical
clinico-genomic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within
"Establishing a dual listing on NYSE Texas reflects both our continued growth as a public company and our deep roots in
"We are proud to welcome Caris Life Sciences to NYSE Texas," said Lynn Martin, President, NYSE Group. "With deep roots in the state and a world-class platform at the forefront of AI and precision medicine, Caris is exactly the kind of innovative company that NYSE Texas was designed to celebrate and support."
Headquartered in
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-dual-listing-on-nyse-texas-302801211.html
SOURCE Caris Life Sciences